Navigation Links
Increased Capacity For Porcine Liver Esterase
Date:6/6/2008

ST. LOUIS, June 6 /PRNewswire/ -- Lee Biosolutions, Inc, a worldwide supplier for porcine liver esterase has announced it has increased its capacity to an industrial scale of over 150 million units per batch size.

Lee Biosolutions supplies Porcine Liver Esterase and other stable high purity enzymes and related proteins to major diagnostic companies used in urine tests as an indicator of blood or urine infection. Porcine liver esterase is also used on a large commercial scale as a biocatalyst in the resolution of mixtures of chiral esters by hydrolysis to produce optically active carboxylic acids.

Lee Biosolutions growth for porcine liver esterase is attributed to meeting stringent customer specifications while maintaining consistent high quality products that out perform other manufacturers on the market. Lee Biosolutions scientific team operates with built-in flexibility, is able to respond in a timely manner and has some of the best scientists working in this industry.

According to Lee Biosolutions President Burton Lee, porcine liver esterase demand has increased significantly over the past 12 months. "We operate with one ear constantly tuned to the diagnostic manufacturing and pharmaceutical community," Lee said. "This helps us stay on top of the latest research being conducted on hydrolase enzymes such as porcine liver esterase and gives us the information we need to stay ahead of their demands."

Lee Biosolutions is a leader in the biomarker industry, providing quality products such as http://www.leebio.com/esterase-porcine-P122 (porcine liver esterase) to clinical labs and researchers around the world, developing tomorrow's cures. For more information on porcine esterase and our capabilities go to http://www.leebio.com or contact:

Press Release Contact Information:

Burton Lee

President

Lee Biosolutions, Inc

314.968.1091

info@leebio.com

This release was issued through WebWire(R). For more information visit http://www.webwire.com.


'/>"/>
SOURCE Lee Biosolutions, Inc
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Dermatologists Report Increased Use of Biologics in the Treatment of Psoriasis
2. Millennium Biotechnologies Announces an Increased Annualized Purchase Commitment Totaling $5.8M from Provider Services, Inc.
3. Nephrologists and Non-Nephrologists Alike Report Increased Attention on Chronic Kidney Disease
4. LifeStem International, Inc. Announces Increased Revenues, Decreased Operating Expenses
5. Increased Drug Related Cardiac Toxicity Leads Gwathmey Preclinical Testing Services to Create Novel Cardionomics(TM) Services for Preclinical Cardiac Safety Screening of Drug Candidates
6. Increased Light Leads to Early Detection: Caliper Life Sciences Introduces Bioware(R) Ultra Cancer Cell Lines
7. APIC Statement on Need for Increased Prevention Measures for Healthcare-Associated Infections (HAIs)
8. Kiwa Bio-Tech Animal Feed Volume Increased 25% in Fourth Quarter of 2007
9. Novo Nordisk Increased Operating Profit by 11% in the First Nine Months of 2007 Based on a 9% Sales Increase and an Improved Gross Margin
10. AMTs Cooperative Research and Development Agreement With NIH to Boost Production Capacity
11. Dragon announces new product launch; increase in annual production output capacity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... , Feb. 17, 2017  Protagonist Therapeutics, ... data on its oral peptide drug candidates, PTG-100 ... of the European Crohn,s and Colitis Organization (ECCO).  ... Barcelona, Spain from February 15 ... detail preclinical data on Protagonist drug candidates PTG-100 ...
(Date:2/16/2017)... GREENWICH, Conn. , Feb. 16, ... focused on venture growth investments in biotechnology and ... Josh Richardson , M.D. to Managing Director. ... companies.  He is a board observer at InfaCare ... Longitude,s investments in Aimmune Therapeutics, Akebia Therapeutics, Cadence ...
(Date:2/16/2017)... , Feb. 16, 2017   Capricor Therapeutics, ... clinical-stage biotechnology company developing first-in-class biological therapies for ... it has elected to terminate its license agreement ... receptor agonists, including Cenderitide. "Our decision ... as we prioritize our efforts to advance our ...
(Date:2/16/2017)...  Dermata Therapeutics, LLC, a biotechnology company developing ... of dermatological diseases, today announced it has completed ... into a $5 million credit facility with Silicon ... capital for general corporate purposes to further Dermata,s ... of serious diseases treated by dermatologists.   ...
Breaking Biology Technology:
(Date:1/24/2017)... 2017 Biopharm Reports has carried out ... of nuclear magnetic resonance spectroscopy (NMR). This involved ... current practices, developments, trends and end-user plans over ... and opportunities. These areas include growth in the ... and innovation requirements, hyphenated NMR techniques, main suppliers ...
(Date:1/19/2017)... and PUNE, India , January 19, 2017 ... Biometric Sensor Market, Opportunities and Forecast, 2014 - 2022," the global biometric ... CAGR of 9.6% from 2016 to 2022. In 2015, Asia-Pacific ... security for both public and private sectors. Continue ... ...
(Date:1/13/2017)... 2017 Sandata Technologies, LLC, a leading ... industry, including Electronic Visit Verification™ (EVV™), announced today ... as Senior Vice President of Product Management. ... homecare experience to Sandata, where he will be ... align Sandata,s suite of solutions with the needs ...
Breaking Biology News(10 mins):